All In Biotech

Drug Trial Radar · NCT04692493

RA-PRO PRAGMATIC TRIAL

A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 924 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

924

Planned (sponsor's estimate)

Start

Sep 22, 2021

Primary completion

May 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute
First posted
Dec 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another TNFi-biologic, i.e., a second TNFi-biologic first. This is not based on solid evidence, but on arbitrary algorithms often proposed by health insurance plans, and/or physician experience and habit (TNFis launched 22 yrs ago vs. the first tsDMARD 8 years ago vs. first non-TNF-biologic launched 17 years ago). This study will fill a critical knowledge gap by generating CER data for important PROs between these treatment options, switching to a non-TNFi biologic or a tsDMARD in patients with active RA despite the use of a TNFi-biologic.

Conditions

  • Rheumatoid Arthritis

Interventions

  • targeted synthetic DMARD classDrug

    Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment

  • non-TNFi-biologic classDrug

    Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional LimitationTime frame: Change from baseline to 12 months

Locations

49 sites in 2 countries. Site status is shown where the registry gives one.

  • East Alabama Arthritis Center PC

    Auburn, Alabama · Recruiting

  • Bendcare, LLC

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • SunValley Arthritis Center, Ltd

    Peoria, Arizona · Recruiting

  • University of Arizona

    Tucson, Arizona · Recruiting

  • Pacific Arthritis Care Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Arthritis Medical Center

    Nipomo, California · Recruiting

  • Turlock Arthritis & Osteoporosis Center,

    Turlock, California · Recruiting

  • Center for Rheumatology Research

    Woodland Hills, California · Recruiting

  • George Munoz MD, PC

    Aventura, Florida · Recruiting

  • American Arthritis and Rheumatology Associates LLC

    Clearwater, Florida · Recruiting

  • CZ Rheumatology

    Coral Springs, Florida · Recruiting

  • American Arthritis and Rheumatology Associates LLC

    Fort Lauderdale, Florida · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Palm Beach Rheumatology and Wellness

    Jupiter, Florida · Recruiting

  • Arthritis & Rheumatology Center of South Florida

    Margate, Florida · Recruiting

  • Life Medical Research Group

    Miami Gardens, Florida · Recruiting

  • Southwest Florida Rheumatology

    Riverview, Florida · Recruiting

  • Southeast Georgia Physician Associates-Rheumatology

    Brunswick, Georgia · Recruiting

  • Indiana University Health

    Carmel, Indiana · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Tufts University

    Boston, Massachusetts · Recruiting

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Recruiting

  • American Arthritis and Rheumatology Associates -Mi PLLC

    Okemos, Michigan · Recruiting

  • Saint Paul Rheumatology, P.A.

    Eagan, Minnesota · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Dr. Jayashree Sinha

    Clovis, New Mexico · Recruiting

  • Inspire Santa Fe Medical Group

    Santa Fe, New Mexico · Recruiting

  • New York University

    New York, New York · Recruiting

  • Hospital for Special Surgery

    New York, New York · Recruiting

  • University Hospital Cleveland Medical Ctr

    Cleveland, Ohio · Recruiting

  • The MetroHealth System

    Cleveland, Ohio · Recruiting

  • Arthritis and Rheumatology of Southwest Ohio

    Liberty Township, Ohio · Recruiting

  • Southern Ohio Rheumatology

    Wheelersburg, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania · Recruiting

  • Rheumatology and Arthritis Care Center

    Exton, Pennsylvania · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • PA Regional Center for Arthritis and Osteoporosis Research

    Wyomissing, Pennsylvania · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.